Skip to Main Content

Bellus Health is reporting Monday negative results from a mid-stage clinical trial of its experimental pill for chronic cough — a disappointing outcome that is forcing the Canadian drug maker to rethink and prolong development plans.

Merck, Bayer, and Shionogi are all working on similar drugs to treat chronic cough, so they benefit from Bellus’ setback. In February, Merck reported positive results from a Phase 3 clinical trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!